NGNE
COM:NEUROGENE
Neurogene
- Stock
Last Close
15.59
22/11 21:00
Market Cap
500.52M
Beta: -
Volume Today
1.06M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|
average inventory | 956.50K - | 1.50M 56.35% | 1.29M 13.94% | |
average payables | 3.48M - | 3.13M 10.04% | 1.61M 48.51% | |
average receivables | 395K - | 890K 125.32% | 25.27M 2,739.16% | |
book value per share | -62.93 - | -99.82 58.63% | 14.51 114.53% | |
capex per share | -12.58 - | -1.53 87.86% | -0.03 98.36% | |
capex to depreciation | -19.40 - | -0.70 96.41% | -0.10 86.03% | |
capex to operating cash flow | 0.40 - | 0.04 89.34% | 0.01 85.21% | |
capex to revenue | ||||
cash per share | 48.32 - | 56.18 16.27% | 15.37 72.63% | |
days of inventory on hand | 306.65 - | 123.11 59.85% | 167.39 35.97% | |
days payables outstanding | 902.48 - | 71.38 92.09% | 290.48 306.96% | |
days sales outstanding | ||||
debt to assets | 0.05 - | 0.04 16.39% | 0.07 70.18% | |
debt to equity | -0.06 - | -0.03 43.25% | 0.09 371.59% | |
dividend yield | ||||
earnings yield | -0.36 - | -3.71 934.53% | -0.15 96.06% | |
enterprise value | 75.41M - | -62.47M 182.84% | 116.57M 286.60% | |
enterprise value over ebitda | -1.52 - | 1.20 178.99% | -2.36 296.52% | |
ev to operating cash flow | -1.63 - | 1.18 172.77% | -2.27 291.69% | |
ev to sales | ||||
free cash flow per share | -44.36 - | -37.71 15.00% | -4.03 89.30% | |
free cash flow yield | -0.46 - | -3.70 704.92% | -0.21 94.38% | |
graham net net | -83.06 - | -117.61 41.59% | 15.48 113.16% | |
graham number | 221.34 - | 291.38 31.64% | 30.40 89.57% | |
income quality | 0.92 - | 0.96 4.21% | 1.42 47.93% | |
intangibles to total assets | 0 - | 0 | 0 | |
interest coverage | -28.26K - | -4.63K 83.61% | ||
interest debt per share | 3.57 - | 3.21 9.94% | 1.27 60.52% | |
inventory turnover | 1.19 - | 2.96 149.08% | 2.18 26.45% | |
invested capital | -0.06 - | -0.03 43.25% | 0.09 371.59% | |
market cap | 140.74M - | 14.86M 89.44% | 248.52M 1,572.13% | |
net current asset value | -119.40M - | -170.28M 42.61% | 163.80M 196.19% | |
net debt to ebitda | 1.32 - | 1.49 12.86% | 2.67 79.70% | |
net income per share | -34.60 - | -37.80 9.25% | -2.83 92.51% | |
operating cash flow per share | -31.78 - | -36.18 13.84% | -4.01 88.92% | |
payables turnover | 0.40 - | 5.11 1,164.36% | 1.26 75.43% | |
receivables turnover | ||||
research and ddevelopement to revenue | ||||
return on tangible assets | -0.50 - | -0.51 1.47% | -0.16 67.70% | |
revenue per share | ||||
roe | 0.55 - | 0.38 31.13% | -0.20 151.55% | |
roic | 0.62 - | 0.41 33.22% | -0.25 161.35% | |
sales general and administrative to revenue | ||||
shareholders equity per share | -62.93 - | -99.82 58.63% | 14.51 114.53% | |
stock based compensation to revenue | ||||
tangible asset value | -91.88M - | -145.74M 58.63% | 186.02M 227.64% | |
tangible book value per share | -62.93 - | -99.82 58.63% | 14.51 114.53% | |
working capital | 63.10M - | 78.07M 23.72% | 177.38M 127.21% |
All numbers in (except ratios and percentages)